Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen

被引:89
作者
Mohty, M
Jacot, W
Faucher, C
Bay, JO
Zandotti, C
Collet, L
Choufi, B
Bilger, K
Tournilhac, O
Vey, N
Stoppa, AM
Coso, D
Gastaut, JA
Viens, P
Maraninchi, D
Olive, D
Blaise, D
机构
[1] Inst J Paoli I Calmettes, Unite Transplantat & Therapie Cellulaire, F-13273 Marseille 09, France
[2] Univ Mediterranee, Marseille, France
[3] Inst J Paoli I Calmettes, Lab Immunol Tumeurs, F-13009 Marseille, France
[4] Ctr Jean Perrin, Unite Transplantat Medullaire, Clermont Ferrand, France
[5] Univ Marseille, Marseille, France
[6] Hop Enfants La Timone, Virol Lab, Ctr Hosp, Marseille, France
[7] Inst J Paoli I Calmettes, Dept Microbiol, F-13009 Marseille, France
[8] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[9] Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France
关键词
infections; allogeneic stem cell transplantation; reduced-intensity conditioning;
D O I
10.1038/sj.leu.2403105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the setting of reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (allo-SCT), the epidemiology of transplant-related infections is still poorly defined. In 101 high-risk patients who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan and antithymocyte globulin (ATG), we report during the first 6 months a cumulative incidence of positive CMV antigenemia of 42% (95% CI 32-52%), developing at a median of 37 (range 7-116) days without evidence of CMV disease (median follow-up, 434 days). The cumulative incidence of bacteremia was 25% (95% CI 17-33%), occurring at a median of 67 (range 7-172) days, while patients had recovered a full neutrophil count. In all, 65% of the bacteremia (95% CI 49-81%) were gram negative. The cumulative incidence of fungal infections was 8% (95% CI 3-13%), with a median onset of 89 (range 7-170) days. In multivariate analysis, stem cell source (bone marrow; P = 0.0002) was significantly associated with the risk of positive CMV antigenemia, while higher doses of prednisone (> 2 mg/kg) represented the major risk factor for bacteremia (P = 0.0001). Infectious-related mortality was 5% (95% CI 1-9%), with aspergillosis being the principal cause. Collectively, these results suggest that prospective efforts are warranted to develop optimal antimicrobial preventive strategies after RIC allo-SCT.
引用
收藏
页码:2168 / 2177
页数:10
相关论文
共 59 条
  • [1] Allison AC, 1996, CLIN TRANSPLANT, V10, P77
  • [2] HIGH-DOSE BOLUS METHYLPREDNISOLONE FOR THE TREATMENT OF ACUTE GRAFT VERSUS HOST-DISEASE
    BACIGALUPO, A
    VANLINT, MT
    FRASSONI, F
    PODESTA, M
    VENEZIANO, G
    AVANZI, G
    VITALE, V
    MARMONT, AM
    [J]. BLUT, 1983, 46 (03): : 125 - 132
  • [3] Invasive mold infections in allogeneic bone marrow transplant recipients
    Baddley, JW
    Stroud, TP
    Salzman, D
    Pappas, PG
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 32 (09) : 1319 - 1324
  • [4] Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Francaise de Greffe de Moelle
    Blaise, D
    Kuentz, M
    Fortanier, C
    Bourhis, JH
    Milpied, N
    Sutton, L
    Jouet, JP
    Attal, M
    Bordigoni, P
    Cahn, JY
    Boiron, JM
    Schuller, MP
    Moatti, JP
    Michalle, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 537 - 546
  • [5] BOECKH M, 1992, BLOOD, V80, P1358
  • [6] Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
    Boeckh, M
    Bowden, RA
    Gooley, T
    Myerson, D
    Corey, L
    [J]. BLOOD, 1999, 93 (05) : 1781 - 1782
  • [7] Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
    Boeckh, M
    Gooley, TA
    Myerson, D
    Cunningham, T
    Schoch, G
    Bowden, RA
    [J]. BLOOD, 1996, 88 (10) : 4063 - 4071
  • [8] Boeckh M, 1999, Transpl Infect Dis, V1, P165, DOI 10.1034/j.1399-3062.1999.010305.x
  • [9] Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma
    Carella, AM
    Cavaliere, M
    Lerma, E
    Ferrara, R
    Tedeschi, L
    Romanelli, A
    Vinci, M
    Pinotti, G
    Lambelet, P
    Loni, C
    Verdiani, S
    De Stefano, F
    Valbonesi, M
    Corsetti, MT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) : 3918 - 3924
  • [10] High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
    Chakrabarti, S
    Mackinnon, S
    Chopra, R
    Kottaridis, PD
    Peggs, K
    O'Gorman, P
    Chakraverty, R
    Marshall, T
    Osman, H
    Mahendra, P
    Craddock, C
    Waldmann, H
    Hale, G
    Fegan, CD
    Yong, K
    Goldstone, AH
    Linch, DC
    Milligan, DW
    [J]. BLOOD, 2002, 99 (12) : 4357 - 4363